By Stephen Nakrosis
Shares of DBV Technologies were trading higher on the Nasdaq after hours Wednesday, following the company confirming alignment with the Food and Drug Administration on an accelerated approval for its Viaskin Peanut Patch in children aged 1 to 3.
In the late-trading session, shares of the biopharmaceutical company were 31% higher, at $4.32. The stock closed the day's regular session with a 4.6% loss, finishing at $3.29.
DBV said it aligned with the FDA on key study design elements for its Comfort Toddlers study, including study size and wear time collection methodology and analysis.
The company also said a biologics license application for the toddlers' indication of the Viaskin Peanut Patch is expected to be submitted in the second half of 2026.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 11, 2024 17:12 ET (22:12 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.